Nothing Special   »   [go: up one dir, main page]

ES2147540B1 - ADTIOSINE HUMAN ANTI RECEIVER ANTIBODIES ANTIBODIES A2B. - Google Patents

ADTIOSINE HUMAN ANTI RECEIVER ANTIBODIES ANTIBODIES A2B.

Info

Publication number
ES2147540B1
ES2147540B1 ES9900373A ES9900373A ES2147540B1 ES 2147540 B1 ES2147540 B1 ES 2147540B1 ES 9900373 A ES9900373 A ES 9900373A ES 9900373 A ES9900373 A ES 9900373A ES 2147540 B1 ES2147540 B1 ES 2147540B1
Authority
ES
Spain
Prior art keywords
receptor
antibodies
polyclonal antibodies
adenosine
adtiosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9900373A
Other languages
Spanish (es)
Other versions
ES2147540A1 (en
Inventor
Montero Josefa Mallol
Perez Maribel Mirabet
Campos Enrique Canela
Biset Carmen Lluis
Fernandez Rafael Franco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Universitat de Barcelona UB
Original Assignee
Universitat Autonoma de Barcelona UAB
Universitat de Barcelona UB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Autonoma de Barcelona UAB, Universitat de Barcelona UB filed Critical Universitat Autonoma de Barcelona UAB
Priority to ES9900373A priority Critical patent/ES2147540B1/en
Priority to PCT/ES2000/000052 priority patent/WO2000049051A1/en
Priority to AU25498/00A priority patent/AU2549800A/en
Publication of ES2147540A1 publication Critical patent/ES2147540A1/en
Application granted granted Critical
Publication of ES2147540B1 publication Critical patent/ES2147540B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos policlonales anti receptor humano A2B de adenosina Se obtienen anticuerpos policlonales por inmunización de conejos con una proteína conjugada con nuevos péptidos cuyas secuencias de aminoácidos (código de una letra) son FQPAQGKNKPKWA y AYRNRDFRYTFHKI, seleccionadas respectivamente a partir del supuesto tercer bucle extracelular, y a partir de una porción del dominio C-terminal, del receptor humano A2B de adenosina. Particularmente, se realiza la conjugación de la hemocianina de lapa (keyhole limpet) utilizando un péptido que presenta una cisteina adicional en el extremo C-terminal y el método de acoplamiento de m-maleimidobenzoil-N-hidroxisuccinimida. Estos anticuerpos policlonales son útiles, o bien por sí mismos como antagionistas, o bien para buscar la presencia o ausencia del receptor humano A2B de adenosina en una muestra (mediante la detección de la presencia o ausencia del complejo formado entre dicho receptor y dicho anticuerpo), lo cual es aplicable en la investigaciónde fármacos.Polyclonal antibodies against human A2B adenosine receptor Polyclonal antibodies are obtained by immunization of rabbits with a protein conjugated with new peptides whose amino acid sequences (one letter code) are FQPAQGKNKPKWA and AYRNRDFRYTFHKI, selected respectively from the so-called third extracellular loop, and from of a portion of the C-terminal domain, of the human adenosine A2B receptor. Particularly, the conjugation of the limpet hemocyanin (keyhole limpet) is performed using a peptide that has an additional cysteine at the C-terminal end and the coupling method of m-maleimidobenzoyl-N-hydroxysuccinimide. These polyclonal antibodies are useful, either by themselves as antagonistic, or to look for the presence or absence of the human adenosine A2B receptor in a sample (by detecting the presence or absence of the complex formed between said receptor and said antibody) , which is applicable in drug research.

ES9900373A 1999-02-15 1999-02-15 ADTIOSINE HUMAN ANTI RECEIVER ANTIBODIES ANTIBODIES A2B. Expired - Fee Related ES2147540B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES9900373A ES2147540B1 (en) 1999-02-15 1999-02-15 ADTIOSINE HUMAN ANTI RECEIVER ANTIBODIES ANTIBODIES A2B.
PCT/ES2000/000052 WO2000049051A1 (en) 1999-02-15 2000-02-15 Human adenosine a2b anti-receptor polyclonal antibodies
AU25498/00A AU2549800A (en) 1999-02-15 2000-02-15 Human adenosine a2b anti-receptor polyclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9900373A ES2147540B1 (en) 1999-02-15 1999-02-15 ADTIOSINE HUMAN ANTI RECEIVER ANTIBODIES ANTIBODIES A2B.

Publications (2)

Publication Number Publication Date
ES2147540A1 ES2147540A1 (en) 2000-09-01
ES2147540B1 true ES2147540B1 (en) 2001-04-01

Family

ID=8307433

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9900373A Expired - Fee Related ES2147540B1 (en) 1999-02-15 1999-02-15 ADTIOSINE HUMAN ANTI RECEIVER ANTIBODIES ANTIBODIES A2B.

Country Status (3)

Country Link
AU (1) AU2549800A (en)
ES (1) ES2147540B1 (en)
WO (1) WO2000049051A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020205753A1 (en) 2019-01-11 2021-08-05 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
GB2264948B (en) * 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors

Also Published As

Publication number Publication date
WO2000049051A1 (en) 2000-08-24
ES2147540A1 (en) 2000-09-01
AU2549800A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
ES2194782T3 (en) IMPROVED PROCEDURE FOR THE DETECTION OF ACIDORRESISTENT BACTERIA OF THE GENDER HELICOBACTER IN THE MAKES.
UY28641A1 (en) ANTIBODIES
ES2525477T3 (en) Humanized anti-factor D antibodies
ES2548327T3 (en) Method to detect proBNP with a monoclonal antibody
CN103509107B (en) Method of preparing bombyx mori silk fibroin specific antibody by utilizing characteristic polypeptide
PE20070183A1 (en) MONOCLONAL ANTIBODIES ANTI-TRKB
FI4209510T3 (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
AR075790A2 (en) ANTI-NGF ANTIBODIES NEUTRALIZING HUMANS AS SELECTIVE INHIBITORS OF THE NGF VIA (NEURAL GROWTH FACTOR)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
CO5700152A1 (en) NEW ANTI-IGF-IR ANTIBODIES AND THEIR USES
CY1107537T1 (en) ANALYSIS OF THE COMPOSITE HCV ANTIGON / ANTIBODY
ECSP034503A (en) CYCLE SELECTIVE PEPTIDES
DE60013287D1 (en) EARLY DETECTION OF FLAVIVIRES USING NS1 GLYCOPROTEIN
RS53984B1 (en) Ip-10 antibodies and their uses
MX2009002711A (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma.
PE20091004A1 (en) HUMAN C-FMS ANTIGEN BINDING PROTEINS
PE20061329A1 (en) HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
PE20150222A1 (en) MULTI-SPECIFIC ANTIBODIES
CO5560582A2 (en) HUMAN ANTIBODY INTEGRATED IN A CDR AND FRAGMENT OF SUCH ANTIBODY
RU2011103199A (en) ANTIBODIES AGAINST CDH3 LABELED BY A RADIO ISOTOPE MARK AND THEIR APPLICATION
CY1106876T1 (en) PACKAGING AND METHOD OF PROTECTION OF ESM-1
PE20220708A1 (en) ANTI-CD73 ANTIBODIES
EP1381864A4 (en) Detection of candida
ES2331414T3 (en) ANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR 23.
PE20090906A1 (en) ANTIBODIES AND ANTI-EPHB4 ANTIBODY FRAGMENTS

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000901

Kind code of ref document: A1

Effective date: 20000901

FD2A Announcement of lapse in spain

Effective date: 20190524